Short answer
Scholar Rock Holding Corp (SRRK) filed its Q3 2025 10-Q quarterly report on Nov 14, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $0 with net income of −$102M.
Q3 2025 key financials · XBRL
- Revenue
- $0
- Net income
- −$102M
- −58.5% YoY · +7.1% QoQ
- EPS (diluted)
- −$0.89
- −34.8% YoY · +9.2% QoQ
Source: XBRL data from the Scholar Rock Holding Corp (SRRK) Q3 2025 10-Q on SEC EDGAR. USD.
Scholar Rock Holding Corp Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No off-balance sheet arrangements during periods presented
- Recent accounting standards reviewed; no material impact identified
- Smaller reporting company status effective Dec 31, 2024; will lose status after June 30, 2025
- Will cease smaller reporting company requirements starting Q1 2026; face additional disclosure rules
- Remain non-accelerated filer through Dec 31, 2026, due to eligibility until Dec 31, 2025
Risk Factors
- New risk: FDA CRL in Sept 2025 on third-party fill-finish facility delays apitegromab BLA resubmission and commercialization progress
- Material update: Impact of 2025 U.S. govt staffing cuts reduces FDA review capacity, risking further regulatory delays for apitegromab
- Regulatory risk: FDA classified fill-finish facility as “official action indicated” (OAI) with Form 483 issued in July 2025, complicating approval process
- Operational risk: Lack of prior commercialization experience and ongoing build-out of compliance, medical affairs, commercial organization may impair apitegromab launch
- Financial risk: Continued net losses and need for additional capital raise to fund ongoing development and commercialization efforts
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Scholar Rock Holding Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.